X-Rx, Gilead in IPF deal

X-Rx Inc. (Waltham, Mass.) and Gilead Sciences Inc. (NASDAQ:GILD) partnered to develop an inhibitor of autotaxin ( ENPP2; ATX) that is in preclinical development to treat idiopathic pulmonary fibrosis.

X-Rx will lead development through Phase I testing. The company will receive an undisclosed upfront payment and research funding, and is eligible for clinical milestones. Gilead holds an option to obtain exclusive, worldwide rights to the program. ...